FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal
Wall Street Journal
A $16.5 billion deal aimed at boosting Novo Nordisk’s production of the weight-loss drug Wegovy is drawing extra scrutiny from U.S. antitrust regulators.
https://www.wsj.com/articles/ftc-seeks-more-info-on-16-5-billion-novo-catalent-deal-704fb4d9